Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • newsofal newsofal Jan 7, 2013 9:43 AM Flag

    SCLN to report in March

    •The Company anticipates 2013 sales revenue of $150 million - $155 million .
    •The Company expects 2013 non-GAAP EPS of $0.66 - $0.72 per share. SciClone's non-GAAP EPS excludes employee stock-based compensation from GAAP EPS.
    •The Company anticipates 2013 year-end cash and investments balances to be greater than $105 million excluding any impacts on cash balances associated with the Company's acquisition of new products, ongoing stock repurchase program and any other unbudgeted one-time cash expenses.
    •The Company expects cash and investments balances to be approximately $87 million (unaudited) at December 31, 2012 . Excluding the cash impact of fourth quarter 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $93 million (unaudited). Excluding the cash impact of the full-year 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $112 million (unaudited).

 
SCLN
9.11-0.04(-0.44%)4:00 PMEDT